← SynDRA
DOFEQUIDAR
SynDRA canonical compound SYN0002862 — structure-anchored drug synonym record
| Clinical phase | Phase 3 |
|---|
| Primary target(s) | ABCB1 |
|---|
| Mechanism of action | P-glycoprotein inhibitor |
|---|
All known targets
Mechanisms of action (all sources)
- MARCKSL1 INHIBITOR
- P-glycoprotein inhibitor
- P glycoprotein inhibitor
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
- CP2C9
- CP3A7
- KSYK
- NSD2
- SYK
Drug classes
Cross-references
Synonyms
- 0BJK6B565B
- dofequidarum
- RefChem:135562
- DTXCID10817702
- Dofequidar [INN]
- MS209
- UNII-0BJK6B565B
- C30H31N3O3
- DOFEQUIDAR [WHO-DD]
- orb1679065
- SCHEMBL2848386
- SCHEMBL29351485
- KLWUUPVJTLHYIM-UHFFFAOYSA-N
- EBC-06062
- MFCD09838435
- NCGC00378575-01
- NCGC00378575-04
- DA-72877
- HY-17013
- EN300-6487183
- BRD-A14941520-051-01-0
- Z278165154
- MS-209 (sesquifumarate)
- C34H35N3O7
- AKOS030526583
- F84996
- Dofequidar (fumarate)
- Dofequidar (sesquifumarate)
- CS-2041
- MFCD00925095
- orb1309752
- SCHEMBL2850163
- SCHEMBL29399301
- HY-17013A
- T11071
- MS-30594
- DA-62988
- Dofequidar Fumarate
Look up DOFEQUIDAR in the interactive SynDRA portal →